PIM1 and prostate carcinoma: Using pull-down, co-immunoprecipitation, and intracellular Ca2+ flow tests, myricetin selectively inhibited Moloney murine leukaemia virus-1 (PIM1) and disrupted the link between PIM1 and CXCR4 to have cytotoxic, pro-apoptotic, and anti-metastatic effects on prostate cancer cells [162].